(Reuters) – The U.S. Food and Drug Administration (FDA) said on Friday it had granted traditional approval for AbbVie’s “guided missile” cancer therapy, Elahere, for adult patients with a type of ovarian and related cancers who have received one to three prior lines of treatment.
(Reporting by Mariam Sunny in Bengaluru)
Comments